ViroPharma Downgraded to “Neutral” at Merrill Lynch (VPHM)
ViroPharma (NASDAQ:VPHM) was downgraded by equities research analysts at Merrill Lynch from a “buy” rating to a “neutral” rating in a research note issued to investors on Wednesday, Analyst Ratings.Net reports.
Several other analysts have also recently commented on the stock. Analysts at Goldman Sachs Group Inc. raised their price target on shares of ViroPharma (NASDAQ:VPHM) from $27.00 to $30.00 in a research note to investors on Wednesday. Separately, analysts at Bank of America Corp. downgraded shares of ViroPharma (NASDAQ:VPHM) from a “buy” rating to an “underperform” rating in a research note to investors on Wednesday. They now have a $34.00 price target on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of ViroPharma (NASDAQ:VPHM) from $41.00 to $47.00 in a research note to investors on Monday. They now have a “buy” rating on the stock.
One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $38.38.
Shares of ViroPharma (NASDAQ:VPHM) traded down 1.91% during mid-day trading on Wednesday, hitting $40.00. 1,880,248 shares of the company’s stock traded hands. ViroPharma has a 1-year low of $22.12 and a 1-year high of $40.89. The stock has a 50-day moving average of $31.56 and a 200-day moving average of $28.2. The company’s market cap is $2.621 billion.
ViroPharma (NASDAQ:VPHM) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.15 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.01 by $0.14. The company had revenue of $104.00 million for the quarter, compared to the consensus estimate of $105.06 million. During the same quarter last year, the company posted ($0.06) earnings per share. ViroPharma’s revenue was up 9.6% compared to the same quarter last year. Analysts expect that ViroPharma will post $-0.78 EPS for the current fiscal year.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.